Concepedia

Author

Kevin Litcofsky

Seres Therapeutics (United States)ORCID

Also Known As

Kevin D Litcofsky, Kevin D. Litcofsky, Kevin Litcofsky, Litcofsky, Kevin

22

Publications

290

Citations

4

H-Index

26

Concepts

All Affiliations

Seres Therapeutics (United States)Mayo Clinic
KL

About

Kevin Litcofsky is an author at Seres Therapeutics (United States) specializing in medicine, antimicrobial drug discovery, and health sciences.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

105

2

Engineering

1

1

94

3

Health Sciences

1

1

11

4

Microbiology

1

1

11

5

Molecular Biology

1

1

94

Kevin Litcofsky

×

4

Publications

266

Citations

4

H-Index

YearCitations

SER-109, an Investigational Microbiome Drug to Reduce Recurrence After <i>Clostridioides difficile</i> Infection: Lessons Learned From a Phase 2 Trial

Barbara McGovern, Christopher B. Ford, Matthew R. Henn,

Clinical Infectious Diseases

2020

150

Iterative plug-and-play methodology for constructing and modifying synthetic gene networks

Kevin Litcofsky, Raffi Afeyan, Russell J. Krom,

Nature Methods

2012

94

1503. Engraftment of Investigational Microbiome Drug, SER-262, in Subjects Receiving Vancomycin Is Associated with Reduced Rates of Recurrence after Primary Clostridium Difficile Infection (CDI)

Christopher B. Ford, Kevin Litcofsky, Barbara McGovern,

Open Forum Infectious Diseases

2019

11

Impact of a Purified Microbiome Therapeutic on Abundance of Antimicrobial Resistance Genes in Patients With Recurrent<i>Clostridioides difficile</i>Infection

Timothy J. Straub, Mary‐Jane Lombardo, Jessica A. Bryant,

Clinical Infectious Diseases

2023

11

Page 1